Michele Di Stefano

Dr. Michele Di Stefano

Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2009 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
KBKyle J. Berean
Kyle J. Berean
NHNam Ha
Nam Ha
JOJian Zhen Ou
Jian Zhen Ou
ACAdam F. Chrimes
Adam F. Chrimes
DGDanilla Grando
Danilla Grando
NDNing Dai
Ning Dai
Breath tests represent a valid and non-invasive diagnostic tool in many gastroenterological conditions. The rationale of hydrogen-breath tests is based on the concept that part of the gas produced by colonic bacterial fermentation diffuses into the blood and is excreted by breath, where it can be quantified easily. There are many differences in the methodology, and the tests are increasingly popular. The Rome Consensus Conference was convened to offer recommendations for clinical practice about the indications and methods of H2-breath testing in gastrointestinal diseases. Experts were selected on the basis of a proven knowledge/expertise in H2-breath testing and divided into Working Groups (methodology; sugar malabsorption; small intestine bacterial overgrowth; oro-coecal transit time and other gas-related syndromes). They performed a systematic review of the literature, and then formulated statements on the basis of the scientific evidence, which were debated and voted by a multidisciplinary Jury. Recommendations were then modified on the basis of the decisions of the Jury by the members of the Expert Group. The final statements, graded according to the level of evidence and strength of recommendation, are presented in this document; they identify the indications for the use of H2-breath testing in the clinical practice and methods to be used for performing the tests.

1 September 2015 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
ASAntonio Di Sabatino
Antonio Di Sabatino
UVUmberto Volta
Umberto Volta
CSChiara Salvatore
Chiara Salvatore
PBPaolo Biancheri
Paolo Biancheri
GCGiacomo Caio
Giacomo Caio
GCGino R. Corazza
Gino R. Corazza

1 July 2012 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
EMEmanuela Miceli
Emanuela Miceli
MLMarco Vincenzo Lenti
Marco Vincenzo Lenti
DPDonatella Padula
Donatella Padula
OLOmbretta Luinetti
Ombretta Luinetti
CVClaudia Vattiato
Claudia Vattiato
GCGino Roberto Corazza
Gino Roberto Corazza

1 May 2000 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
Michele Di StefanoMichele Di Stefano
Michele Di Stefano
SMS Malservisi
S Malservisi
GVG Veneto
G Veneto
AFA Ferrieri
A Ferrieri
GCG R Corazza
G R Corazza

22 May 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MLMarco Vincenzo Lenti
Marco Vincenzo Lenti
EMEmanuela Miceli
Emanuela Miceli
SCSara Cococcia
Sara Cococcia
CKCatherine Marie Klersy
Catherine Marie Klersy
MSMartina Staiani
Martina Staiani
ASAntonio Di Sabatino
Antonio Di Sabatino
Summary: Background: Autoimmune atrophic gastritis (AAG) is characterised by a wide clinical spectrum that could delay its diagnosis.Aims: To quantify the diagnostic delay in patients suffering from AAG and to explore possible risk factors for longer diagnostic delay.Methods: Consecutive patients with AAG evaluated at our gastroenterological outpatient clinic between 2009 and 2018 were included. Diagnostic delay was estimated as the time lapse occurring between the appearance of the first likely symptoms, laboratory alterations, and other clues indicative of AAG and the final diagnosis. Patient‐dependent and physician‐dependent diagnostic delays were also assessed. Multivariable regression models were fitted.Results: 291 patients with AAG (mean age at diagnosis 61 ± 15 years; F:M ratio = 2.3:1) were included. The median overall diagnostic delay was 14 months (interquartile range [IQR] 4‐41). Factors associated with longer median overall diagnostic delay were female sex (17 months, IQR 5‐48), having a previous misdiagnosis (36 months, IQR 17‐125) and a history of infertility/miscarriages (33 months, IQR 8‐120), whereas a higher level of education was associated with longer patient‐dependent diagnostic delay (4 months, IQR 1‐12). First evaluation by a gastroenterologist was associated with a median longer diagnostic delay (6 months, IQR 2‐15) compared to an internist (3 months, IQR 3‐31) and a haematologist (1 month, IQR 0‐2). Age, socioeconomic or marital status did not affect the diagnostic delay.Conclusions: AAG is burdened by substantial diagnostic delay, especially in female patients, and due to lack of awareness, particularly among gastroenterologists. Uncommon vitamin B12 deficiency‐related manifestations are overlooked and may prolong the diagnostic delay.

17 October 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
EMEmanuela Miceli
Emanuela Miceli
AVAlessandro Vanoli
Alessandro Vanoli
MLMarco Vincenzo Lenti
Marco Vincenzo Lenti
CKCatherine Klersy
Catherine Klersy
Michele Di StefanoMichele Di Stefano
Michele Di Stefano
ASAntonio Di Sabatino
Antonio Di Sabatino
Summary: Background: Autoimmune atrophic gastritis (AAG) is an immune‐mediated disorder characterised by destruction of gastric oxyntic mucosaAim: To explore gastric histopathological evolution in a cohort of AAG patients over a prolonged follow‐upMethods: Single centre prospective study enrolling consecutive patients with histologically confirmed AAG between 2000 and 2018. All AAG patients undergoing endoscopic follow‐up every 1‐3 years were classified as having stages 1, 2 or 3 according to atrophy severity (mild, moderate and severe). AAG patients with either glandular or neuroendocrine dysplasia/neoplasia were classified as having stage 4. Disease stage progression, and changes in serum anti‐parietal cell antibody (PCA), chromogranin A and gastrin‐17 were assessed.Results: In total, 282 AAG patients (mean age 60.3 years; F:M ratio 2.4:1; median follow‐up 3 years, interquartile range 1‐7) were enrolled. All patients with stages 1 or 2 progressed to stage 2 or 3 over time with a steady trend (P = .243) and regression from a severe to a milder stage was never noticed. Disease progression of patients with stages 1 or 2 occurred within the first 3 years. PCA positivity rate did not change over time. Stage 3 patients had higher gastrin‐17 levels compared to patients with stages 1 and 2 (median 606 vs 295 pg/mL; P < .001). In stage 3, the hazard ratio for the risk of developing stage 4 was 6.6 (95% CI 1.5‐29; P = .001).Conclusions: AAG is a steadily progressive disease, in which stages 1 and 2 always progress to stage 3. The risk of developing a complicated disease stage is greater in patients with more severe gastric lesions.